Tryptophan, glutamine, leucine, and micronutrient supplementation improves environmental enteropathy in Zambian adults: a randomized controlled trial

• Published in: The American journal of clinical nutrition 2019-11, Vol.110 (5), p.1240-1252
• Main Authors: Louis-Auguste, John, Besa, Ellen, Zyambo, Kanekwa, Munkombwe, Derick, Banda, Rosemary, Banda, Themba, Watson, Alastair, Mayneris-Perxachs, Jordi, Swann, Jonathan, Kelly, Paul
• Format: Article
• Language: English
• Subjects: Adult; Adults; Amino acids; Amino Acids - administration & dosage; Bacterial Translocation; Biomarkers; CD4 antigen; clinical trial; Clinical trials; confocal endomicroscopy; Correlation; Dietary Supplements; environmental enteropathy; Female; Fluorescein; Glutamine; Glutamine - administration & dosage; Humans; Intestinal Diseases - prevention & control; Intestinal Mucosa - pathology; Intestine; Intestine, Small - metabolism; Lamina propria; Leucine; Leucine - administration & dosage; Lymphocytes; Male; Mechanistic Target of Rapamycin Complex 1 - metabolism; Metabolism; Metabolites; Metabolomics; Micronutrients; Micronutrients - administration & dosage; Microorganisms; Middle Aged; morphometry; MTOR; Original Research Communications; Randomization; Rapamycin; Residential areas; Supplements; TOR protein; Translocation; Tryptophan; Tryptophan - administration & dosage; Villus; Zambia
• ISSN: 0002-9165; 1938-3207
• DOI: 10.1093/ajcn/nqz189

Environmental enteropathy (EE) refers to villus blunting, reduced absorption, and microbial translocation in children and adults in tropical or deprived residential areas. In previous work we observed an effect of micronutrients on villus height (VH). We aimed to determine, in a randomized controlled trial, if amino acid (AA) or multiple micronutrient (MM) supplementation can improve intestinal structure or barrier dysfunction in Zambian adults with EE. AA (tryptophan, leucine, and glutamine) and/or MM supplements were given for 16 wk in a 2 × 2 factorial comparison against placebo. Primary outcomes were changes in VH, in vivo small intestinal barrier dysfunction assessed by confocal laser endomicroscopy (CLE), and mechanistic (or mammalian) target of rapamycin complex 1 (MTORC1) nutrient responsiveness in lamina propria CD4+ lymphocytes. Over 16 wk AA, but not MM, supplementation increased VH by 16% (34.5 μm) compared with placebo (P = 0.04). Fluorescein leak, measured by CLE, improved only in those allocated to both AA and MM supplementation. No effect was seen on MTORC1 activation, but posttreatment MTORC1 and VH were correlated (ρ = 0.51; P = 0.001), and change in MTORC1 was correlated with change in VH in the placebo group (ρ = 0.63; P = 0.03). In secondary analyses no effect was observed on biomarkers of microbial translocation. Metabolomic analyses suggest alterations in a number of microbial- and host-derived metabolites including the leucine metabolite β-hydroxy-β-methylbutyrate, which was increased by AA supplementation and correlated with VH. In this phase 2 trial, AA supplementation protected against a decline in VH over the supplementation period, and improved barrier function when combined with micronutrients. Leucine and MTORC1 metabolism may be involved in the mechanism of effect. This trial was registered at www.pactr.org as PACTR201505001104412.